ADTX on OTC
Aditxt, Inc.
$0.00 up 0.00 (0.00%)Price as of Oct 15, 2026 at 14:59 UTC
Last updated Oct 16, 2026.
Overview
Compare with One World Products, Inc., Processa Pharmaceuticals, Inc. or ZIOPHARM Oncology, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
8.4%Gross margin4
-612542.2%Operating margin4
-1349028.2%Net margin4
-97.6%Revenue growth, 20254
-768.3%Return on equity4
-$25.7MFree cash flow4
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue0¢$2.9K
- Research and development100¢$3.2M
Out of $3.2K in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Sales | $3.2K | $134.0K |
| Cost of goods sold | $2.9K | $627.5K |
| Gross profit (loss) | $268 | -$493.5K |
| General and administrative expenses $0 and $33,071in stock-based compensation, respectively | $16.0M | $16.3M |
| Research and development $10,000 and $6,712,663 in stock-based compensation, respectively | $3.2M | $10.9M |
| Sales and marketing $473,311 and $0 in stock-based compensation, respectively | $402.0K | $197.9K |
| Total operating expenses | $19.6M | $27.4M |
| NET LOSS FROM OPERATIONS | -$19.6M | -$27.9M |
| Interest expense | -$681.2K | -$4.2M |
| Interest income | $200.2K | $1.5K |
| Amortization of debt discount | -$1.7M | -$3.2M |
| Gain (loss) on note exchange agreement | -$208.7K | |
| Change in fair value of derivative liability | $14.5K | $414.5K |
| Change in fair value of Evofem warrants | $2.8M | |
| Impairment of Evofem F-1 Preferred Stock | -$23.8M | |
| Bargain purchase gain from purchase of Evofem convertible notes | $328.1K | |
| Impairment of fixed assets | -$412.0K | |
| Total other expense | -$23.2M | -$7.2M |
| Net loss before income taxes | -$42.8M | -$35.0M |
| Deemed Dividends | -$1.4M | -$5.9M |
| NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST | -$1.1M | -$573.6K |
| NET LOSS ATTRIBUTABLE TO ADITXT, INC. & SUBSIDIARIES | -$43.1M | -$40.4M |
| Net loss per share, basic (in Dollars per share) | -$1,153.83 | -$22,147,415.22 |
| Net loss per share, diluted (in Dollars per share) | -$1,153.83 | -$22,147,415.22 |
| Weighted average number of shares outstanding during the period, basic (in Shares) | 37.4K shares | 2 shares |
| Weighted average number of shares outstanding during the period, diluted (in Shares) | 37.4K shares | 2 shares |
| Net Loss | -$42.8M | -$35.0M |
| Change in valuation of Evofem note | $1.3M | |
| TOTAL COMPREHENSIVE LOSS | -$41.5M | -$35.0M |
| Stock-based compensation | $32.9K |
Every line of the balance sheet in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $3.2M | $833.0K | |
| Accounts receivable, net | $43.4K | ||
| Inventory | $5.8K | $11.2K | |
| Prepaid expenses | $617.4K | $3.4K | |
| Subscription receivable | $1.1M | ||
| TOTAL CURRENT ASSETS | $3.8M | $2.0M | |
| Fixed assets, net | $880.2K | $1.5M | |
| Intangible assets, net | $2.8K | $6.1K | |
| Deposits | $61.6K | $87.7K | |
| Right of use asset | $1.2M | $1.2M | |
| Convertible notes receivable, at fair value | $3.9M | ||
| Investment in Evofem | $6.6M | $27.3M | |
| TOTAL ASSETS | $16.5M | $32.1M | |
| Accounts payable and accrued expenses | $7.7M | $13.2M | |
| Stock payable | $2.2M | ||
| Notes payable, related party | $115.0K | ||
| Notes payable, net of discount | $1.9M | $5.5M | |
| Financing on fixed assets | $147.8K | ||
| Deferred rent | $53.4K | $106.1K | |
| Operating lease liability, current | $808.2K | $683.4K | |
| TOTAL CURRENT LIABILITIES | $12.2M | $23.4M | |
| Operating lease liability, long term | $342.9K | $436.4K | |
| Derivative liability | $2 | $14.5K | |
| TOTAL LIABILITIES | $12.6M | $23.9M | |
| TOTAL MEZZANINE EQUITY | $7.2M | ||
| Common stock, $0.001 par value, 1,000,000,000 and 100,000,000 shares authorized, 411,500 and 194 shares issued and 411,499 and 193 shares outstanding, respectively | $412 | $1 | |
| Treasury stock, 1 and 1 shares, respectively | -$201.6K | -$201.6K | |
| Additional paid-in capital | $214.4M | $170.0M | |
| Accumulated deficit | -$209.8M | -$168.1M | |
| Accumulated other comprehensive income | $1.3M | ||
| TOTAL ADITXT, INC. STOCKHOLDERS EQUITY | $5.6M | $1.7M | |
| NON-CONTROLLING INTEREST | -$1.7M | -$583.2K | |
| TOTAL STOCKHOLDERS EQUITY | $4.0M | $1.1M | $16.0M |
| TOTAL LIABILITIES, MEZZANINE EQUITY, AND STOCKHOLDERS EQUITY | $16.5M | $32.1M | |
| Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in Shares) | 3.0M shares | 3.0M shares | |
| Preferred stock, shares issued (in Shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in Shares) | 0 shares | 0 shares | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in Shares) | 1.0B shares | 100.0M shares | |
| Common stock, shares issued (in Shares) | 411.5K shares | 194 shares | |
| Common stock, shares outstanding (in Shares) | 411.5K shares | 193 shares | |
| Treasury stock (in Shares) | 1 shares | 1 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$42.8M | -$35.0M |
| Stock-based compensation | $473.3K | $33.1K |
| Stock-based compensation from asset purchase | $10.0K | $6.7M |
| Depreciation expense | $269.3K | $613.9K |
| Amortization of intangible assets | $3.3K | $3.3K |
| Amortization of debt discount - note payable | $1.7M | $3.2M |
| Amortization of debt discount - note receivable | -$220.7K | |
| Loss on note exchange agreement | $208.7K | |
| Modification of warrants for debt issuance costs | $376.9K | |
| New principal from extension of notes, net of debt discount | $452.0K | |
| Change in fair value of derivative liability | -$14.5K | -$414.5K |
| Change in fair value of Evofem warrants | -$2.8M | |
| Impairment of Evofem F-1 preferred stock | $23.8M | |
| Disposal of fixed assets | $3.0K | |
| Bargain purchase gain from purchase of Evofem convertible notes | -$328.1K | |
| Impairment of fixed assets | $412.0K | |
| Accounts receivable | $43.4K | $364.9K |
| Prepaid expenses | -$614.0K | $214.0K |
| Deposits | $26.1K | $18.7K |
| Inventory | $5.5K | $734.3K |
| Accounts payable and accrued expenses | -$5.6M | $5.1M |
| Settlement liability | $667.0K | |
| Net cash used in operating activities | -$25.7M | -$16.8M |
| Purchase of fixed assets | -$13.7K | |
| Investment in convertible notes receivable and warrants | -$2.4M | |
| Investment in Evofem F-1 preferred stock | -$5.0M | |
| Net cash used in investing activities | -$2.4M | -$5.0M |
| Proceeds from notes payable, related party | $678.0K | $467.0K |
| Proceeds from notes and convertible notes payable, net of offering costs | $1.2M | $4.1M |
| Repayments of note payable, related party | -$793.0K | -$727.0K |
| Repayments of note payable | -$6.6M | -$5.3M |
| Common stock, preferred stock, and warrants issued for cash, net of issuance costs | $44.1M | $21.2M |
| Cash from subscription receivable | $1.1M | $4.3M |
| Proceeds from exercises of warrants | $1.2M | |
| Redemptions of A-1 preferred stock | -$308.0K | |
| Redemptions of C-1 preferred stock | -$8.9M | -$2.9M |
| Redemptions of D-1 preferred stock | -$32 | |
| Net cash provided by financing activities | $30.5M | $22.5M |
| NET INCREASE IN CASH | $2.4M | $735.9K |
| Cash paid for interest | $2.5M | $1.2M |
| Issuance of shares for the conversion of notes payable | $500.0K | |
| Debt discount from shares issued as inducement for note payable | $1.6M | |
| Warrant modification | $5.9M | |
| Issuance of shares in asset purchase | $266.4K | |
| Shares issued for settlement | $1.6M | |
| Return of notes payable from Evofem merger agreement | $11.2M | |
| Accrued interest rolled into notes payable | $33.8K | $538.2K |
| Settlement of liability for Series C-1 Convertible Preferred Stock | $667.0B | |
| Exchange of warrants for Series C-1 convertible preferred stock | $6.0M | |
| Derivative liability from conversion feature on preferred stock | $429.0K | |
| ELOC payable | $328.1K | |
| Series C-1 redemption payable | $237.5K | $1.4M |
| ELOC commitment fee stock payable | $2.2M | $2.2M |
| Loan in escrow | $2.0M | |
| Reclassification of series A-1 preferred shares to liabilities | $517.4K | |
| Write off of financed asset | $147.8K | |
| Initial recognition of lease liability and right of use asset | $800.4K |
Former names
- ADiTx Therapeutics, Inc.Nov 23, 2020 to Jul 6, 20213
Recent filings
- Oct 7, 202625-NSE
- Sep 23, 20268-K CURRENT REPORT
- Aug 19, 20268-K CURRENT REPORT
- Jul 17, 20268-K CURRENT REPORT
- Jul 2, 2026SCHEDULE 13G
- Jul 2, 2026SCHEDULE 13G/A
- Jun 26, 2026SCHEDULE 13G
- Jun 25, 2026SCHEDULE 13D/A
- Jun 25, 20264 PRIMARY DOCUMENT
- Jun 24, 20268-K CURRENT REPORT
- Jun 24, 2026SCHEDULE 13G/A
- Jun 24, 2026SCHEDULE 13G/A
- Jun 24, 2026SCHEDULE 13G/A
- Jun 24, 20264 PRIMARY DOCUMENT
- Jun 24, 20263 PRIMARY DOCUMENT
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARAditxt, Inc. filings on SEC EDGAR
- 2Yahoo FinanceADTX quote
- 3SEC EDGARAditxt, Inc. filings on SEC EDGAR
- 4SEC EDGARAditxt, Inc. 10-K for fiscal 2025
- 5SEC EDGARAditxt, Inc. 10-K for fiscal 2021
- 6SEC EDGARAditxt, Inc. 10-K for fiscal 2022
- 7SEC EDGARAditxt, Inc. 10-K for fiscal 2023
- 8SEC EDGARAditxt, Inc. 10-K for fiscal 2019
- 9SEC EDGARAditxt, Inc. 10-K for fiscal 2020
- 10SEC EDGARAditxt, Inc. 10-Q for fiscal 2025
- 11SEC EDGARAditxt, Inc. 10-Q for fiscal 2025
- 12SEC EDGARAditxt, Inc. 10-Q for fiscal 2026